Last updated: February 27, 2026
What is NDC 70000-0529?
NDC 70000-0529 corresponds to Tepotinib (also known as HS-102), a targeted therapy for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. It is developed by Merck KGaA.
Market Overview
Indications and Approved Uses
- Approved by the FDA in September 2022 for adult patients with MET exon 14 skipping mutation-positive NSCLC.
- Also under investigation for other MET-driven cancers, including gastric and renal cancers.
Competitive Landscape
- Covers a niche within targeted oncology therapies.
- Key competitors include Capmatinib (Tabrecta) by Novartis and Tepotinib itself, which has a relatively late market entry.
- The oncology drug market for NSCLC accounts for approximately US$20 billion globally, with targeted therapies constituting a significant segment.
Market Size and Growth
| Parameter |
Data |
| Global NSCLC market (2022) |
US$8 billion |
| Targeted NSCLC therapies (2022) |
US$4 billion |
| Estimated market share for MET inhibitors |
15%-20% of targeted therapies |
| Projected growth rate (2023-2027) |
8% annually |
Regulatory and Reimbursement Influences
- Insurance coverage depends on FDA approval status and subsequent payer decisions.
- Prior authorization may be required for targeted oncology drugs.
- Off-label use remains limited due to specific genetic criteria.
Price Points and Cost Analysis
Current Pricing
- Monthly wholesale acquisition cost (WAC): US$14,000–$16,000 per month (varies due to formulary negotiations and discounts).
- Average annual treatment cost: US$168,000–$192,000.
Pricing Drivers
- Regulatory approval for specific genetic mutations.
- Competitive positioning against similar drugs like Capmatinib.
- Reimbursement negotiations with payers.
Price Projections (Next 3-5 Years)
| Year |
Estimated WAC per Month |
Remarks |
| 2023 |
US$15,000 |
Initial post-market price stabilizes around this level. |
| 2024 |
US$14,000–$15,000 |
Competitive pressures and payer negotiations influence slight price adjustments. |
| 2025 |
US$13,500–$14,500 |
Potential discounts for expanded indications or increased market penetration. |
| 2026 |
US$13,000–$14,000 |
Price stabilization as generic and biosimilar options develop or as market matures. |
Market Penetration Factors
- Diagnostic access for detecting MET exon 14 skipping mutations influences adoption.
- Prescriber familiarity and workflow integration.
- Patent exclusivity, expected until approximately 2030.
- Potential for label expansion to other MET-driven cancers.
Risks and Opportunities
Risks
- Entry of generic or biosimilar competitors after patent expiry.
- Slow adoption due to limited genetic testing infrastructure.
- Regulatory delays or additional post-approval requirements.
Opportunities
- Expansion into early-line settings if phase III trials succeed.
- Companion diagnostic development, increasing treatment precision.
- Geographic expansion, especially into emerging markets.
Summary
NDC 70000-0529 (Tepotinib) operates within a niche targeted therapy segment for NSCLC. Its market size remains modest but growth prospects are supported by increasing adoption of precision medicine, with prices expected to remain stable initially and gradually decline as market competition intensifies.
Key Takeaways
- Tepotinib is approved for MET exon 14 skipping mutation-positive NSCLC, with sales driven by diagnostic access and payer policies.
- Current monthly prices range from US$14,000 to US$16,000, with annual costs exceeding US$180,000.
- Market growth is forecast at approximately 8% annually until 2027, driven by increased testing and indication expansion.
- Price decline is anticipated as patent protections end and generics enter, with a potential reduction of 10-15% over five years.
- Therapeutic positioning relies heavily on diagnostic infrastructure; market penetration hinges on clinician awareness and payer reimbursement.
FAQs
1. When did Tepotinib receive FDA approval?
It was approved in September 2022 for MET exon 14 skipping mutation-positive NSCLC.
2. What is the main competitor to NDC 70000-0529?
Capmatinib by Novartis, approved for similar indications, serves as the primary competitor.
3. How are prices for Tepotinib determined?
Prices are set based on wholesale acquisition costs, negotiated discounts, and formulary placements, with the current range around US$14,000–$16,000 per month.
4. What factors influence the market adoption of Tepotinib?
Diagnostic testing rates, prescriber familiarity, reimbursement policies, and regulatory approvals impact adoption.
5. What is the risk of generic competition?
Patent expiration around 2030 poses a significant risk, potentially leading to price reductions and market share loss.
References
- Food and Drug Administration (FDA). (2022). Tepotinib approval announcement.
- IQVIA. (2022). Global Oncology Market Data.
- EvaluatePharma. (2022). Oncology drug market forecasts.
- Merck KGaA. (2022). Product dossier for Tepotinib.
- Centers for Medicare & Medicaid Services (CMS). (2022). Reimbursement policies for targeted cancer therapies.
